Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Leqvio inclisiran Primary hypercholesterolemia Do not reimburse Complete
Levemir Insulin detemir Diabetes mellitus Do not list Complete
Levemir Insulin detemir Diabetes mellitus Type1, Pediatrics Do not list Complete
Levemir Insulin detemir Diabetes mellitus Withdrawn
Levemir Insulin detemir Diabetes mellitus Do not list Complete
Libtayo cemiplimab Basal cell carcinoma Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Libtayo Cemiplimab Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Locally advanced or metastatic NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Livmarli maralixibat Alagille syndrome Reimburse with clinical criteria and/or conditions Complete